Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RZLTVery BearishCorporate Developmentsnews

High materiality9/10

Rezolute Faces Major Stock Plunge and Fraud Investigations Following Phase 3 Trial Failures

Dec 11, 2025, 8:11 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The 90% stock drop indicates severe loss of investor confidence, reminiscent of companies like Ionis Pharmaceuticals after negative trial results. Such failures can significantly limit funding and operational capacity, leading to a prolonged struggle for RZLT.

AI summary

What happened, with direct paths to the underlying reporting

RZLT's stock dropped nearly 90% after Phase 3 trial failure. The trial did not meet the primary endpoint for ersodetug. Securities law investigations may ensue following this announcement. Potential investor actions could arise due to the trial's outcome. Phase 3 failure raises significant concerns for RZLT's future.

RZLT's stock dropped nearly 90% after Phase 3 trial failure.
The trial did not meet the primary endpoint for ersodetug.
Securities law investigations may ensue following this announcement.
Potential investor actions could arise due to the trial's outcome.
Phase 3 failure raises significant concerns for RZLT's future.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.